Research programme: synthetic macrocycles - Ensemble Therapeutics/Bristol-Myers Squibb

Drug Profile

Research programme: synthetic macrocycles - Ensemble Therapeutics/Bristol-Myers Squibb

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb; Ensemble Discovery
  • Developer Bristol-Myers Squibb; Ensemble Therapeutics
  • Class Macrocyclic compounds; Small molecules
  • Mechanism of Action Protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Unspecified

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Undefined in USA (PO)
  • 05 Jan 2012 Alliance between Ensemble Therapeutics and Bristol-Myers Squibb extended
  • 22 Jun 2010 Ensemble Discovery is now called Ensemble Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top